Predicting ventricular arrhythmia inducibility in ajmaline-induced Brugada type I pattern: Validation of the dST-Tiso interval.

Brugada syndrome ajmaline test programmed ventricular stimulation sudden cardiac death

Journal

Journal of cardiovascular electrophysiology
ISSN: 1540-8167
Titre abrégé: J Cardiovasc Electrophysiol
Pays: United States
ID NLM: 9010756

Informations de publication

Date de publication:
25 Jun 2024
Historique:
revised: 29 01 2024
received: 06 12 2023
accepted: 08 06 2024
medline: 26 6 2024
pubmed: 26 6 2024
entrez: 26 6 2024
Statut: aheadofprint

Résumé

The dST-Tiso is a newly proposed electrocardiographic (ECG) marker during Brugada (BrS) type I pattern, that predicts the likelihood of ventricular arrhythmia (VA) inducibility in patients with ajmaline-induced pattern. The objective of this study was to validate the effectiveness of this criterion using an independent data set. Consecutive patients exhibiting a BrS type I ECG pattern following ajmaline administration underwent programmed ventricular stimulation (PVS). dST-Tiso interval was measured in all patients and tested as a predictor for positive VA inducibility. Among 128 patients (median age 43 years, 59% male) with drug-induced BrS type I ECG pattern who underwent PVS, 32 (25.0%) had VA inducibility that required defibrillation. Compared to noninducible subjects, those with positive PVS were more commonly male (81% vs. 51%, p = 0.003), had longer PQ (165 vs. 160 ms, p = 0.016) and dST-Tiso (310 vs. 230 ms, p < 0.001) intervals, and shorter QT interval (412 vs. 420 ms, p = 0.022). When treated as a continuous variable, dST-Tiso confirmed significant association with VA inducibility, with an adjusted odds ratio of 1.02 (95% confidence interval: 1.01-1.03, p < 0.001) for each 1 ms increase in duration. A dST-Tiso interval >300 ms yielded a sensitivity of 75%, a specificity of 86%, and positive and negative predictive values of 69% and 91%, respectively. The validation of the model based on the dST-Tiso interval >300 ms confirmed its high accuracy in predicting VA inducibility in drug-induced BrS type I pattern. This straightforward ECG marker might be linked to the extent of the electrical substrate of the disease.

Identifiants

pubmed: 38923783
doi: 10.1111/jce.16348
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024 Wiley Periodicals LLC.

Références

Sieira J, Brugada P. The definition of the Brugada syndrome. Eur Heart J. 2017;38:3029‐3034.
Zeppenfeld K, Tfelt‐Hansen J, de Riva M, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43(40):3997‐4126.
Iacopino S, Chierchia GB, Sorrenti P, et al. dST‐Tiso interval, a novel electrocardiographic marker of ventricular arrhythmia inducibility in individuals with ajmaline‐induced Brugada type I pattern. Am J Cardiol. 2021;159:94‐99.
Priori SG, Gasparini M, Napolitano C, et al. Risk stratification in Brugada syndrome. J Am Coll Cardiol. 2012;59:37‐45.
Justice AC, Covinsky KE, Berlin JA. Assessing the generalizability of prognostic information. Ann Intern Med. 1999;130:515‐524.
Gaita F, Cerrato N, Giustetto C, et al. Asymptomatic patients with Brugada ECG pattern: long‐term prognosis from a large prospective study. Circulation. 2023;148:1543‐1555. doi:10.1161/CIRCULATIONAHA.123.064689
Cerrato N, Giustetto C, Gribaudo E, et al. Prevalence of type 1 Brugada electrocardiographic pattern evaluated by twelve‐lead twenty‐four‐hour Holter monitoring. Am J Cardiol. 2015;115(1):52‐56.
Conte G, Sieira J, Sarkozy A, et al. Life‐threatening ventricular arrhythmias during ajmaline challenge in patients with Brugada syndrome: incidence, clinical features, and prognosis. Heart Rhythm. 2013;10:1869‐1874.
Iqbal M, Putra ICS, Pranata R, et al. Electrocardiographic markers indicating right ventricular outflow tract conduction delay as a predictor of major arrhythmic events in patients with brugada syndrome: a systematic review and meta‐analysis. Front Cardiovasc Med. 2022;9:931622.
Gaita F, Cerrato N, Saglietto A, Caponi D, Calò L, Giustetto C. The Brugada syndrome: risk stratification. Eur Heart J Suppl. 2023;25(suppl C):27.
Pappone C, Santinelli V, Mecarocci V, et al. Brugada syndrome: new insights from cardiac magnetic resonance and electroanatomical imaging. Circ Arrhythm Electrophysiol. 2021;14(11):e010004.
Rossi A, Giannoni A, Nesti M, et al. Prognostic value of right ventricular refractory period heterogeneity in type‐1 Brugada electrocardiographic pattern. Europace. 2023;25(2):651‐659.

Auteurs

Saverio Iacopino (S)

Maria Cecilia Hospital, GVM Care & Research, Cotignola, Ravenna, Italy.

Emmanuel Fabiano (E)

Maria Cecilia Hospital, GVM Care & Research, Cotignola, Ravenna, Italy.

Paolo Sorrenti (P)

Maria Cecilia Hospital, GVM Care & Research, Cotignola, Ravenna, Italy.

Andrea Petretta (A)

Maria Cecilia Hospital, GVM Care & Research, Cotignola, Ravenna, Italy.

Jacopo Colella (J)

Maria Cecilia Hospital, GVM Care & Research, Cotignola, Ravenna, Italy.

Alessandro Di Vilio (A)

Maria Cecilia Hospital, GVM Care & Research, Cotignola, Ravenna, Italy.

Giovanni Statuto (G)

Maria Cecilia Hospital, GVM Care & Research, Cotignola, Ravenna, Italy.

Pasquale Filannino (P)

Maria Cecilia Hospital, GVM Care & Research, Cotignola, Ravenna, Italy.

Paolo Artale (P)

Maria Cecilia Hospital, GVM Care & Research, Cotignola, Ravenna, Italy.

Daniele Giacopelli (D)

Clinical Research Unit, BIOTRONIK Italia, Vimodrone, Milano, Italy.

Gianluca Peluso (G)

Maria Cecilia Hospital, GVM Care & Research, Cotignola, Ravenna, Italy.

Gennaro Fabiano (G)

Maria Cecilia Hospital, GVM Care & Research, Cotignola, Ravenna, Italy.

Giuseppe Campagna (G)

Maria Cecilia Hospital, GVM Care & Research, Cotignola, Ravenna, Italy.

Federico Cecchini (F)

Maria Cecilia Hospital, GVM Care & Research, Cotignola, Ravenna, Italy.

Classifications MeSH